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The monoclonal antibody GL-013, with specific binding reactivity in vitro to human tumors of the gastrointestinal tract, was radioiodinated and injected intraperitoneally into nude mice bearing human gastric carcinoma xenografts SY86 B (moderately differentiated glandular adenocarcinoma) and SY86 D (signet ring cell carcinoma). Whole body scintigraphy indicated tumor localization with 131I-labeled MAb GL-013 , but not with 131I-labeled normal mice immunoglobulin . The best tumor contrast was obtained between days 3 and 7 after injection.
As confirmation of the imaging results, 131I-GL-013 preferentially localized in tumor tissue compared with normal tissue and 131I-GL-013 gave a higher tumor uptake ratio than the control 131I-NMIgG (at day 9 after injection), as determined by tissue counting of radioactivity. These results demonstrate that MAb GL-013 localizes in xenografts SY86 B and SY86 D and the possible clinical application of MAb GL-013 to radioimmunolocalization . 
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